Company research / ESLA
Estrella Immunopharma, Inc. (ESLA)
- Sector Manufacturing
- Fiscal year ends around Dec 31
Beyond the statements
Follow the company.
Explore new filings, reported insider transactions and company relationships.
Annual financials
| Period ended | TTM to 2026-06-30 | 2025-12-31 | 2024-12-31 | 2024-06-30 | 2023-06-30 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|---|
| R&D Expense | $6.98M | $10.25M | n/a | $4.11M | $10.45M | n/a | n/a |
| Operating Income | -$9.68M | -$13.06M | n/a | -$7.31M | -$11.11M | n/a | -$249.1K |
| Net Income | -$10.01M | -$13.06M | n/a | -$7.31M | -$11.11M | n/a | -$247.7K |
| EPS (Diluted) | n/a | -$0.35 | n/a | -$0.27 | -$36.35 | n/a | n/a |
| Total Assets | $1.82M | $3.18M | $3.14M | $4.45M | $3.03M | $9.72M | $45.80M |
| Total Liabilities | $9.26M | $13.54M | $3.00M | $180.7K | $9.77M | $2.65M | $1.62M |
| Shareholders' Equity | -$7.43M | -$10.37M | $143.7K | $4.27M | -$11.74M | -$2.26M | -$1.01M |
| Cash & Equivalents | $100.0K | $1.38M | $916.9K | $4.17M | $2.48M | $40.8K | $478.9K |
| Operating Cash Flow | -$9.38M | -$1.79M | n/a | -$16.07M | -$1.34M | n/a | -$316.2K |
| Shares Outstanding | n/a | n/a | n/a | 36.61M | 978.2K | 1.42M | 1.42M |
| Weighted Average Diluted Shares | n/a | 36.82M | n/a | 27.10M | 305.7K | n/a | 1.18M |
| EPS (Basic) | n/a | -$0.35 | n/a | -$0.27 | -$36.35 | n/a | n/a |